Spinal cord stimulators (SCSs) are neuromodulation devices implanted in the epidural space with the goal of treating chronic pain that fails to respond to conventional treatment. SCSs have been increasingly used in recent years
1,2; approximately 50 000 are implanted annually in the US
3 at a cost of approximately $3.5 billion.
4 Some have advocated for greater use of SCSs to reduce risks of medications, including opioids and gabapentinoids.
5